A multicenter study identifies a new biomarker for vascular dementias

Credit: CC0 Public Domain

Vascular dementia is caused by a defect on blood flow arrival to the brain, which consequently generates neuronal damage. Until now, its diagnosis has been quite complicated because only neuroimaging methods, such as a scanner, and the appearance of symptoms were available. The lack of more precise and specific methods creates confusion with other neurodegenerative diseases, like Alzheimer's. A study, developed between Medical Center of Göttingen University (UMG) and Bellvitge Biomedical Research Institute (IDIBELL), has described a new biomarker for this disease, lipocalin 2 protein. This protein is present in the cerebrospinal fluid that bathes the brain.

Patient samples from four have unequivocally demonstrated that the of people affected by vascular dementia has higher levels of lipocalin 2. Patients from four European centers have participated in this multicenter study: Sahlgrenska University Hospital (Sweden), the University of Coimbra (Portugal), the University Paris Diderot (France) and the University Medical Center of Göttingen (Germany); and has been led by Dr. Franc Llorens, researcher from IDIBELL and the Center for Biomedical Research in Neurodegenerative Diseases Network (CIBERNED), and Dr. Inga Zerr (UMG). The result reproducibility in four sample groups converts lipocalin 2 to a firm candidate for vascular dementias diagnosis.

In contrast to diagnosis methods available until now, lipocalin 2 could discriminate vascular dementia from Alzheimer's, since the second does not show lipocalin 2 increase. The study shows that only patients with vascular dementia, but not those with cerebral vascular damage without dementia, exhibit this increase. The high diagnostic specificity of this protein further highlights its potential as a biomarker.

To determine the role of lipocalin 2 in the brain of patients with vascular dementia, brain tissue samples from the biobank HUB-ICO-IDIBELL (Bellvitge University Hospital, Catalan Institute of Oncology and IDIBELL) were studied. These studies were performed with the collaboration of Dr. Isidre Ferrer, head of the Neuropathology group of IDIBELL and CIBERNED, and showed that are expressing lipocalin 2, and its expression pattern is different in or Alzheimer's.

More information: Franc Llorens et al, Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia, Nature Communications (2020). DOI: 10.1038/s41467-020-14373-2

Journal information: Nature Communications

Citation: A multicenter study identifies a new biomarker for vascular dementias (2020, January 30) retrieved 28 September 2023 from https://medicalxpress.com/news/2020-01-multicenter-biomarker-vascular-dementias.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Analyzing a protein from cerebrospinal fluid will help diagnose patients with prion diseases


Feedback to editors